Geneva Capital Management LLC lessened its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 2.3% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 889,707 shares of the company’s stock after selling 20,577 shares during the period. Omnicell comprises 2.0% of Geneva Capital Management LLC’s investment portfolio, making the stock its 6th biggest holding. Geneva Capital Management LLC’s holdings in Omnicell were worth $115,547,000 at the end of the most recent reporting period.
Several other institutional investors also recently modified their holdings of the company. Vantage Consulting Group Inc purchased a new stake in Omnicell in the 4th quarter valued at $46,000. Archer Investment Corp lifted its holdings in shares of Omnicell by 50.0% during the 4th quarter. Archer Investment Corp now owns 450 shares of the company’s stock worth $54,000 after acquiring an additional 150 shares during the period. Public Employees Retirement System of Ohio lifted its holdings in shares of Omnicell by 21.7% during the 4th quarter. Public Employees Retirement System of Ohio now owns 522 shares of the company’s stock worth $63,000 after acquiring an additional 93 shares during the period. Fieldpoint Private Securities LLC lifted its holdings in shares of Omnicell by 247.1% during the 1st quarter. Fieldpoint Private Securities LLC now owns 486 shares of the company’s stock worth $63,000 after acquiring an additional 346 shares during the period. Finally, Parallel Advisors LLC raised its holdings in Omnicell by 37.8% in the fourth quarter. Parallel Advisors LLC now owns 558 shares of the company’s stock valued at $67,000 after buying an additional 153 shares during the period. Institutional investors and hedge funds own 99.24% of the company’s stock.
OMCL stock traded down $2.31 during mid-day trading on Wednesday, reaching $131.43. The company had a trading volume of 175 shares, compared to its average volume of 388,941. The company has a quick ratio of 3.68, a current ratio of 4.12 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $5.68 billion, a P/E ratio of 153.72, a P/E/G ratio of 3.68 and a beta of 1.04. Omnicell, Inc. has a one year low of $56.16 and a one year high of $146.99. The stock’s 50-day simple moving average is $137.65 and its two-hundred day simple moving average is $121.80.
Several research firms recently commented on OMCL. TheStreet lowered shares of Omnicell from a “b” rating to a “c+” rating in a report on Friday, April 30th. Craig Hallum raised their price target on shares of Omnicell from $100.00 to $142.00 and gave the company a “buy” rating in a report on Thursday, January 14th. Piper Sandler raised their price target on shares of Omnicell from $147.00 to $152.00 and gave the company an “overweight” rating in a report on Thursday, May 6th. Finally, Benchmark lifted their price objective on shares of Omnicell from $155.00 to $160.00 and gave the company a “buy” rating in a research note on Thursday, May 6th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $120.50.
Omnicell, Inc, together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Featured Story: What is the QQQ ETF?
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.